Evaluation of Dupilumab in Children With Uncontrolled Asthma
Completed · Phase 3 · NCT02948959
Conditions: Asthma
At a glance
- Research payments reported, 2025
- $30,250
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 408
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (drug), Asthma Controller Therapies (drug), Asthma Reliever Therapies (drug)
- Dates
- Started 2017-04-21; completion 2020-08-26
- Results posted
- Yes
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (\<) 12 years of age with uncontrolled persistent asthma. Secondary Objective: To evaluate in children 6 to \<12 years of age with uncontrolled persistent asthma: * The safety and tolerability of dupilumab. * The evaluate the effect of dupilumab in improving participant reported outcomes including health related quality of life. * The dupilumab systemic exposure and incidence of anti-drug antibodies. * The evaluate the association between dupilumab treatment and pediatric immune responses to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza vaccine.
From ClinicalTrials.gov, last updated 2022-03-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $30,250 in research payments for this study in 2025 (74 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $30,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.